Other CIS Countries


The country is landlocked country in Eastern Europe, bordered clockwise by Russia to the northeast.

Economy Overview

  • Population: 9.85M ( (2009 est.)
  • Urban Population is 80%
  • GDP (PPP) (2009 est.)
  • Total : USD 120.8 B, Per Capita: USD 12,737
  • Currency- Bellarusian Ruble, 1 USD =  2980-3000 Belarusian Ruble

Pharmaceutical Market Overview

  • Market Size: $540 M (18%  growth).Total No. of Apteka: 2554, share of private retail outlet  is just 31%
  • On WHO ranking, Belarus healthcare system is ranked at 53rd.
  • At present only 49 out of 618 drugs are manufactured locally, rest all are exported. In fact, about 50% of Belarus medicine manufacturing is exported (mainly to the CIS markets). The industry is dominated by state-owned companies. The majority of private companies are small or medium-sized. In 2008 the Belarusian Government issued lists of enterprises to be reorganized into open joint stock companies (505 enterprises) and to be privatized during 2008-2010 (144 enterprises).

Viva Group in Belarus

A team of 20 professionals are promoting 10 products in 7 therapeutic segments in 17 markets to 3500 customers doctors / aptekas ) in Belarus. Five major distributors in the country are working with us for availability of products. Five major distributors are operational for availability of products.


Moldova is the second smallest of former Soviet republics and most densely populated. It is landlocked, bounded by Ukraine on the east and Romania to the west.

  • Population: 4.5 Million
  • GDP: USD 10.21 B GDP growth -6.6% (2009 est.)
  • GDP per capita :USD 2,400
  • Currency: Moldovan leu
  • Moldova is ranked 19th out of 20 countries in the Emerging Europe Regional Rankings. Pharmaceutical market was valued at US$208m in 2009. The market is growing CAGR of 5% between 2009 and 2014 in USD, increasing to 8.45% growth between 2009 and 2019 in local currency. Market is dominated by low-priced drugs and generic medicines. Nevertheless, the government has increased the health insurance budget by 30% in 2009 and has pledged to provide free insurance to low-income families. This should help the market to develop as it will increase access to both medicines and healthcare. Additionally, Moldova has claimed to make significant progress in tackling counterfeit pharmaceuticals over the past five years, with automated accounting systems for drug distribution, which had been implemented by 74% of pharmaceutical enterprises by the end of 2008, being an important contributing factor.

Viva Group in Moldova

  • A team of 20 professionals is promoting 12 products in 5 therapeutic segments in 14 markets to 4000 customers (doctors / aptekas ) in Moldova.
  • Two major distributors are responsible for availability of products.


Smaller country of Soviet Union in Central Asia region

Population: 7.35 M

Total GDP : 13.66 Billion (09 estimate)

Viva Group in Tajikistan

  • Well established registered office –Micro Biotec LLC with full licensed Warehouse
  • Total field force: 10 MR’s , 1 RM, 1 Country Executive, 1 BDM
  • Promoting 24 products
  • Customer Coverage: 2000 Drs, 1200 Pharmacies and all major distributors


Located in Central Asia, landlocked and muntaineous.

Population: 4.8 M

GDP (PPP): Total $ 12.101B

Per Capita: $ 2253

Currency: Som

Viva group in Kyrgyzstan

  • Field Force: 35 MR’s, 7 RM’s, 2 BDM’s
  • Will set up own legal company, warehouse and field force  by 2011


  • Due to strict govt. regulations with 100% restrictions on foreign companies, tied up with leading distribution companies
  • Marketing team is managed under distributor 
  • Due to strict govt. regulations with 100% restrictions on foreign companies, tied up with leading distribution companies
  •  Marketing team is managed under distributor 


Population: 27.3M Growth Rate: 0.9%

Age Structure: 0-14 years: 28.1%; 15-64 years: 67%;

Sex Ratio: Total population 0,99 Males / Female

Life Expectancy: Total population: 71.96 years;

Male: 68.95 years; Female: 75.15 years

Key Economic Indicators

Improvements in the economy   

  • GDP: USD 44.89 Billion (2008)
  • Per Capita GDP in 2008: USD 1561
  • Currency-Uzbek Som, 1 USD = 1627 UZS
  • Urban Population is more than 35.8%

  • The Central Bank often delays or restricts convertibility, especially for consumer goods. Currency conversion procedures liberalized but restrictions remain.
  • However, Some Govt., Semi-Govt. and Govt. supported organizations enjoy full conversion facilities. Doing Business with these organizations.
  • A number of different ways like conversion through commodity exchange are also in practice – but expensive in terms of currency conversion rates.

Uzbekistan Healthcare Market

Healthcare Expenditure % of GDP-5%

No. of Doctors: 72000

No. of Hospitals: 4199

  • The Ministry of Health is a structural division of the Cabinet of Ministers which is headed by the President. The Cabinet of Ministers is responsible for developing National Health policies and Financing the system.
  • Post Independence, still in transition and the Healthcare system has moved from central planning and government financing to a mixed public and private system .
  • The public expenditure on health care has been maintained at about 5% of GDP year over year.
  • Govt. purchases through tenders are very limited and are a very small part of the budget funding.
  • Due to above factors and the privatization program by the Government, the private healthcare sector is seeing tremendous growth since last few years.
  • Pharmaceutical market is the most attractive business sector in Uzbekistan with minimal limitations (in comparison to other business sectors) e.g. VAT, minimum import duties etc. (VAT may be introduced).
  • Since 1994, prices for few basic drugs have been fixed.  For all other products, price regulation has come into effect which controls maximum wholesale and retail mark-ups (20% for imported medicines and 25% for locally manufactured medicines ).
  • The limitation on foreign-currency exchange might explain the existing black market for pharmaceuticals.
  • Over 60% of the market is dominated by generics (brands) from Russia, Ukraine, China and India Lately following has been observed
  • Increase in Non CIS imports which shows acceptance of quality and branded Generics.
  • There has been decrease in unit growth of pharmaceuticals but with increasing value which shows there has been increased prices in Uzbekistan  
  • There has been observed decreasing imports from companies of CIS countries that shows  surge in local manufacturing in Uzbekistan.

Viva Group in Uzbekistan

  • Due to poor foreign currency regulations and slow business cycle, soon launching formal operation
  • 30 products are already registered
  • Recently started with local company formation, licensed warehouse, marketing team


  • Had full fledged operation with legal locally formed company
  • We had to withdraw due to changes in MOH rules to ban Indian manufacturers export
  • Now operations are being reviewed with Non-Indian manufacturers